Search

Displaying results 2451 - 2460 of 10000 in total
  1. Drug

    Bromotheophylline

    go.drugbank.com/drugs/DB14018
    Approved

    [L1082] It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.[L1113] … From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome.

  2. Drug

    Halazepam

    go.drugbank.com/drugs/DB00801
    ApprovedIllicitWithdrawn

    [A1212, A178114] It has been shown to be less toxic than chlordiazepoxide or diazepam. … [A1212] This drug is no longer marketed in the United States, and was withdrawn by _Schering_, its manufacturer, in 2009.[L6226, L6229]

  3. Drug

    Rescinnamine

    go.drugbank.com/drugs/DB01180
    Approved

    Rescinnamine is an angiotensin-converting enzyme inhibitor used as an antihypertensive drug. It is an alkaloid obtained from Rauwolfia serpentina and other species of Rauwolfia.

    Synonyms: Trimethoxy cinnamoyl reserpate de methylCategories: Agents Acting on the Renin-Angiotensin System
  4. Drug

    Ursodeoxycholic acid

    go.drugbank.com/drugs/DB01586
    ApprovedInvestigational

    [A256272] UDCA works by replacing the hydrophobic or more toxic bile acids from the bile acid pool.[A256272] … [A256267,A256463] UDCA was first characterized in the bile of the Chinese black bear and is formed by 7b-epimerization of [chenodeoxycholic acid], which is a primary bile acid.

    Products: T-RUXICO
  5. Drug

    Rituximab

    go.drugbank.com/drugs/DB00073
    ApprovedInvestigational

    On November 28, 2018, the US FDA approved _Truxima_, the first biosimilar to Rituxan (Rituximab) [L4808]. … It was originally approved by the U.S.

    Products: MABTHERA ® CONCENTRADO DE SOLUCIÓN PARA INFUSIÓN 500 MG / 50 ML
  6. Drug

    Delandistrogene moxeparvovec

    go.drugbank.com/drugs/DB16802
    ApprovedInvestigational

    [A260256] DMD tends to be more prevalent in males. … It was granted accelerated approval by the FDA on June 22, 2023, as the first gene therapy to treat Duchenne Muscular Dystrophy (DMD).

  7. Drug

    Remoxipride

    go.drugbank.com/drugs/DB00409
    ApprovedWithdrawn

    [A215422] It gained approval in the UK in 1989 but was withdrawn in 1993 after it was found to be associated with an increased incidence of aplastic anemia.[A215422,A215512]

    Categories: Dopamine D2 Receptor Antagonists
  8. Drug

    Clobetasol propionate

    go.drugbank.com/drugs/DB01013
    ApprovedInvestigational

    [L11815] It has demonstrated superior activity compared to [fluocinonide][A190963] and was first described in the literature in 1974.

    Synonyms: Clobetasol propionate EInternational brands: Embeline E
  9. Drug

    Indalpine

    go.drugbank.com/drugs/DB08953
    ApprovedWithdrawn

    Indalpine was one of the first selective serotonin reuptake inhibitors to reach the American market. It was initially marketed by Pharmuka. … However, after the emergence of widespread concern regarding adverse effects caused by SSRIs, and reported hematological effects caused by Indalpine, it was abruptly withdrawn from the US market.

    Categories: Serotonergic Drugs Shown to Increase Risk of Serotonin Syndrome
  10. Drug

    Sarecycline

    go.drugbank.com/drugs/DB12035
    ApprovedInvestigational

    Based upon data from Global Burden of Disease studies, the acne vulgaris condition affects up to 85% of young adults aged 12 to 25 years globally - with the possibility of permanent physical and mental … The acne often presents physically as a mixture of non-inflammatory and inflammatory lesions mainly on the face but on the back and chest as well [L4814].